# Solid Biosciences Inc.: financial statements, quarterly

SLDB · Nasdaq · CIK 1707502 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sldb.md) · [Financials](/companies/sldb/financials.md) · [Filings](/companies/sldb/filings.md) · [Insiders](/companies/sldb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sldb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [16.7](/filings/0000950170-24-122247.md) | [15.5 d](/filings/0000950170-25-034644.md) | [18.9](/filings/0000950170-25-072560.md) | [19.5](/filings/0000950170-25-107279.md) | [27.3](/filings/0001193125-25-262818.md) | [30.8 d](/filings/0001193125-26-115928.md) | [30.9](/filings/0001193125-26-219337.md) | [32.4](/filings/0001193125-26-337935.md) | [38.9](/filings/0001193125-25-262818.md) | [38.1 d](/filings/0001193125-26-115928.md) | [46.1](/filings/0001193125-26-219337.md) | [44.3](/filings/0001193125-26-337935.md) |
| Operating income | $m | [(23.1)](/filings/0000950170-24-122247.md) | [(22.3) d](/filings/0000950170-25-034644.md) | [(26.9)](/filings/0000950170-25-072560.md) | [(27.8)](/filings/0000950170-25-107279.md) | [(35.2)](/filings/0001193125-25-262818.md) | [(39.9) d](/filings/0001193125-26-115928.md) | [(40.1)](/filings/0001193125-26-219337.md) | [(41.7)](/filings/0001193125-26-337935.md) | [(48.1)](/filings/0001193125-25-262818.md) | [(49.4) d](/filings/0001193125-26-115928.md) | [(57.3)](/filings/0001193125-26-219337.md) | [(57.4)](/filings/0001193125-26-337935.md) |
| Interest expense | $m | [0.1](/filings/0000950170-24-122247.md) | [0.1 d](/filings/0000950170-25-034644.md) | [0.1](/filings/0000950170-24-060034.md) | [0.1](/filings/0000950170-24-096130.md) | [0.1](/filings/0001193125-25-262818.md) | [0.1 d](/filings/0001193125-26-115928.md) | [0.1](/filings/0001193125-26-219337.md) | [0.1](/filings/0001193125-26-337935.md) | [(0.3)](/filings/0001193125-25-262818.md) | [0.0 d](/filings/0001193125-26-115928.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-23-061096.md) | [0.0 d](/filings/0000950170-25-034644.md) | [0.0](/filings/0000950170-24-060034.md) | [0.0](/filings/0000950170-24-096130.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(21.0)](/filings/0000950170-24-122247.md) | [(20.3) d](/filings/0000950170-25-034644.md) | [(24.3)](/filings/0001193125-25-262818.md) | [(25.1)](/filings/0001193125-25-262818.md) | [(32.7)](/filings/0001193125-25-262818.md) | [(42.6) d](/filings/0001193125-26-115928.md) | [(39.3)](/filings/0001193125-26-337935.md) | [(39.5)](/filings/0001193125-26-337935.md) | [(45.8)](/filings/0001193125-25-262818.md) | [(49.8) d](/filings/0001193125-26-115928.md) | [(56.7)](/filings/0001193125-26-337935.md) | [(54.8)](/filings/0001193125-26-337935.md) |
| Diluted EPS | $ per share | [(1.05)](/filings/0000950170-24-122247.md) | not reported | [(0.64)](/filings/0000950170-25-072560.md) | [(0.61)](/filings/0000950170-25-107279.md) | [(0.79)](/filings/0001193125-25-262818.md) | not reported | [(0.59)](/filings/0001193125-26-219337.md) | [(0.42)](/filings/0001193125-26-337935.md) | [(0.48)](/filings/0001193125-25-262818.md) | not reported | [(0.52)](/filings/0001193125-26-219337.md) | [(0.38)](/filings/0001193125-26-337935.md) |
| Basic EPS | $ per share | [(1.05)](/filings/0000950170-24-122247.md) | not reported | [(0.64)](/filings/0000950170-25-072560.md) | [(0.61)](/filings/0000950170-25-107279.md) | [(0.79)](/filings/0001193125-25-262818.md) | not reported | [(0.59)](/filings/0001193125-26-219337.md) | [(0.42)](/filings/0001193125-26-337935.md) | [(0.48)](/filings/0001193125-25-262818.md) | not reported | [(0.52)](/filings/0001193125-26-219337.md) | [(0.38)](/filings/0001193125-26-337935.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [49.0](/filings/0000950170-24-122247.md) | [74.0](/filings/0000950170-25-034644.md) | [118](/filings/0000950170-25-072560.md) | [95.9](/filings/0000950170-25-107279.md) | [64.4](/filings/0001193125-25-262818.md) | [80.2](/filings/0001193125-26-115928.md) | [211](/filings/0001193125-26-219337.md) | [139](/filings/0001193125-26-337935.md) | [61.4](/filings/0001193125-25-262818.md) | [59.9](/filings/0001193125-26-337935.md) | [297](/filings/0001193125-26-219337.md) | [159](/filings/0001193125-26-337935.md) |
| Current assets | $m | [148](/filings/0000950170-23-061096.md) | [130](/filings/0000950170-25-034644.md) | [214](/filings/0000950170-24-060034.md) | [198](/filings/0000950170-24-096130.md) | [179](/filings/0000950170-24-122247.md) | [157](/filings/0001193125-26-115928.md) | [313](/filings/0000950170-25-072560.md) | [279](/filings/0000950170-25-107279.md) | [245](/filings/0001193125-25-262818.md) | [205](/filings/0001193125-26-337935.md) | [397](/filings/0001193125-26-219337.md) | [395](/filings/0001193125-26-337935.md) |
| Total assets | $m | [185](/filings/0000950170-23-061096.md) | [165](/filings/0000950170-25-034644.md) | [249](/filings/0000950170-24-060034.md) | [231](/filings/0000950170-24-096130.md) | [212](/filings/0000950170-24-122247.md) | [189](/filings/0001193125-26-115928.md) | [344](/filings/0000950170-25-072560.md) | [308](/filings/0000950170-25-107279.md) | [274](/filings/0001193125-25-262818.md) | [233](/filings/0001193125-26-337935.md) | [423](/filings/0001193125-26-219337.md) | [421](/filings/0001193125-26-337935.md) |
| Current liabilities | $m | [15.8](/filings/0000950170-23-061096.md) | [14.5](/filings/0000950170-25-034644.md) | [14.3](/filings/0000950170-24-060034.md) | [14.7](/filings/0000950170-24-096130.md) | [22.9](/filings/0000950170-24-122247.md) | [30.3](/filings/0001193125-26-115928.md) | [28.8](/filings/0000950170-25-072560.md) | [29.8](/filings/0000950170-25-107279.md) | [36.3](/filings/0001193125-25-262818.md) | [33.5](/filings/0001193125-26-337935.md) | [30.3](/filings/0001193125-26-219337.md) | [28.6](/filings/0001193125-26-337935.md) |
| Total liabilities | $m | [40.4](/filings/0000950170-23-061096.md) | [38.5](/filings/0000950170-25-034644.md) | [38.0](/filings/0000950170-24-060034.md) | [37.7](/filings/0000950170-24-096130.md) | [44.8](/filings/0000950170-24-122247.md) | [51.4](/filings/0001193125-26-115928.md) | [49.4](/filings/0000950170-25-072560.md) | [50.0](/filings/0000950170-25-107279.md) | [56.0](/filings/0001193125-25-262818.md) | [52.5](/filings/0001193125-26-337935.md) | [48.8](/filings/0001193125-26-219337.md) | [46.5](/filings/0001193125-26-337935.md) |
| Shareholders' equity | $m | [144](/filings/0000950170-24-122247.md) | [126](/filings/0001193125-26-115928.md) | [211](/filings/0001193125-25-262818.md) | [193](/filings/0001193125-25-262818.md) | [167](/filings/0001193125-25-262818.md) | [137](/filings/0001193125-26-337935.md) | [294](/filings/0001193125-26-337935.md) | [258](/filings/0001193125-26-337935.md) | [218](/filings/0001193125-25-262818.md) | [180](/filings/0001193125-26-337935.md) | [374](/filings/0001193125-26-337935.md) | [374](/filings/0001193125-26-337935.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.9) d](/filings/0000950170-24-122247.md) | [(20.8) d](/filings/0000950170-25-034644.md) | [(25.2)](/filings/0000950170-25-072560.md) | [(21.5) d](/filings/0000950170-25-107279.md) | [(23.7) d](/filings/0001193125-25-262818.md) | [(29.6) d](/filings/0001193125-26-115928.md) | [(31.9)](/filings/0001193125-26-219337.md) | [(37.4) d](/filings/0001193125-26-337935.md) | [(33.5) d](/filings/0001193125-25-262818.md) | [(53.6) d](/filings/0001193125-26-115928.md) | [(47.2)](/filings/0001193125-26-219337.md) | [(52.6) d](/filings/0001193125-26-337935.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-122247.md) | [0.1 d](/filings/0000950170-25-034644.md) | [0.1](/filings/0000950170-25-072560.md) | [0.3 d](/filings/0000950170-25-107279.md) | [0.0 d](/filings/0001193125-25-262818.md) | [0.2 d](/filings/0001193125-26-115928.md) | [0.1](/filings/0001193125-26-219337.md) | [0.4 d](/filings/0001193125-26-337935.md) | [0.1 d](/filings/0001193125-25-262818.md) | [0.6 d](/filings/0001193125-26-115928.md) | [0.2](/filings/0001193125-26-219337.md) | [0.2 d](/filings/0001193125-26-337935.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.5](/filings/0000950170-23-061096.md) | [19.6](/filings/0000950170-24-060034.md) | [19.7](/filings/0000950170-24-096130.md) | [20.1](/filings/0000950170-24-122247.md) | [38.2](/filings/0000950170-25-072560.md) | [40.9](/filings/0000950170-25-107279.md) | [41.4](/filings/0001193125-25-262818.md) | [66.3](/filings/0001193125-26-219337.md) | [94.1](/filings/0001193125-26-337935.md) | [94.4](/filings/0001193125-25-262818.md) | [110](/filings/0001193125-26-219337.md) | [144](/filings/0001193125-26-337935.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 107,225,238 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337935.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.